شركة AbbVie Inc. (ABBV): نموذج الأعمال التجارية

في المشهد الديناميكي للابتكار الصيدلاني، تبرز شركة AbbVie Inc. كقوة تحويلية، حيث تصمم نموذج أعمالها بشكل استراتيجي لإعادة تعريف العلاجات الطبية ورعاية المرضى. ومن خلال الاستفادة من شبكة معقدة من الشراكات، والقدرات البحثية المتطورة، والنهج الذي يركز على الليزر للحلول الطبية المعقدة، وضعت AbbVie نفسها كشركة رائدة عالميًا في تطوير علاجات رائدة في علم المناعة والأورام. يكشف هذا النموذج الشامل لنموذج الأعمال عن الآلية المتطورة وراء النجاح الملحوظ الذي حققته شركة AbbVie، ويقدم لمحة عميقة عن كيفية قيام هذا العملاق الصيدلاني بتحويل الخبرة العلمية إلى تدخلات طبية تغير الحياة.

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: الشراكات الرئيسية

التعاون الاستراتيجي مع مؤسسات البحوث الصيدلانية

تحتفظ شركة AbbVie بشراكات بحثية استراتيجية مع المؤسسات التالية:

مؤسسة	التركيز على البحوث	سنة الشراكة
جامعة شيكاغو	أبحاث المناعة	2022
جامعة ستانفورد	تطوير أدوية الأورام	2023
كلية الطب بجامعة هارفارد	أبحاث علم الأعصاب	2021

اتفاقيات الترخيص مع شركات التكنولوجيا الحيوية

تتضمن اتفاقيات ترخيص AbbVie ما يلي:

• Genmab A/S: التعاون في تطوير الأجسام المضادة
• علوم الحياة كاليكو: أبحاث الشيخوخة وطول العمر
• شركة Regenxbio: تقنيات العلاج الجيني

المشاريع المشتركة لتطوير الأدوية والتجارب السريرية

شريك	منطقة المخدرات / العلاج	مبلغ الاستثمار
إنفينيتي للأدوية	التجارب السريرية للأورام	250 مليون دولار
أليرجان	تطوير أدوية علم الأعصاب	63 مليار دولار (الاستحواذ)

الشراكات مع شبكات توزيع الرعاية الصحية العالمية

تشمل شراكات التوزيع العالمية لشركة AbbVie ما يلي:

• شركة ماكيسون: توزيع الأدوية في أمريكا الشمالية
• AmerisourceBergen: لوجستيات الرعاية الصحية العالمية
• الكاردينال هيلث: إدارة سلسلة التوريد الدوائية

التحالفات مع المراكز الطبية الأكاديمية

المركز الطبي	مجال البحث التعاوني	التمويل السنوي
مايو كلينيك	أبحاث المناعة	45 مليون دولار
مركز إم دي أندرسون للسرطان	أبحاث الأورام	38 مليون دولار
جامعة جونز هوبكنز	أمراض التنكس العصبي	32 مليون دولار

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: الأنشطة الرئيسية

البحث والتطوير الصيدلاني

استثمرت شركة AbbVie 7.04 مليار دولار أمريكي في البحث والتطوير في عام 2022، وهو ما يمثل 19.1% من إجمالي الإيرادات. تركز الأبحاث على علم المناعة والأورام وعلم الأعصاب وعلم الفيروسات.

سنة الاستثمار في البحث والتطوير	المبلغ الإجمالي	نسبة الإيرادات
2022	7.04 مليار دولار	19.1%

اكتشاف الأدوية والاختبارات السريرية

تحتفظ AbbVie بخط تطوير سريري واسع النطاق يضم أكثر من 50 برنامجًا للمرحلة السريرية عبر مجالات علاجية متعددة.

• ما يقرب من 25 كيانًا جزيئيًا جديدًا محتملًا في التطوير السريري
• تجارب سريرية نشطة عبر أكثر من 20 مؤشرًا علاجيًا
• متوسط معدل نجاح التجارب السريرية 12.5%

تصنيع المنتجات الصيدلانية الحيوية

وتدير شركة AbbVie 24 منشأة تصنيع عالمية بقدرة إنتاجية تبلغ 3.2 مليار جرعة سنويًا.

مواقع التصنيع	إجمالي المرافق	القدرة الإنتاجية السنوية
مواقع التصنيع العالمية	24	3.2 مليار جرعة

تسويق وتسويق الأدوية المتخصصة

وحققت شركة AbbVie مبيعات بقيمة 58.05 مليار دولار أمريكي خلال عام 2022، مع المنتجات الرئيسية بما في ذلك Humira وSkyrizi وRinvoq.

• مبيعات هوميرا: 21.2 مليار دولار في 2022
• مبيعات Skyrizi: 5.4 مليار دولار في 2022
• مبيعات رينفوق: 3.8 مليار دولار في 2022

الابتكار المستمر في علاجات المناعة والأورام

استثمرت شركة AbbVie موارد كبيرة في تطوير علاجات متقدمة للحالات الطبية المعقدة.

المنطقة العلاجية	عدد البرامج البحثية النشطة	القيمة السوقية المحتملة
علم المناعة	18	45 مليار دولار
الأورام	22	55 مليار دولار

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: الموارد الرئيسية

محفظة واسعة النطاق للملكية الفكرية

تمتلك AbbVie أكثر من 43000 براءة اختراع عالمية اعتبارًا من عام 2023. وتبلغ قيمة محفظة براءات اختراع Humira حوالي 20 مليار دولار. تشتمل محفظة براءات الاختراع الخاصة بعلم الأعصاب على أكثر من 2500 براءة اختراع نشطة.

فئة براءات الاختراع	عدد براءات الاختراع	القيمة المقدرة
براءات الاختراع المناعية	15,600	14.5 مليار دولار
براءات اختراع الأورام	8,700	9.2 مليار دولار
براءات الاختراع في علم الأعصاب	2,500	3.8 مليار دولار

مرافق البحث والتطوير المتقدمة

بلغ إجمالي الاستثمار في البحث والتطوير 6.4 مليار دولار في عام 2023. وتدير 7 مراكز بحث عالمية رئيسية في جميع أنحاء أمريكا الشمالية وأوروبا.

• شمال شيكاغو، إلينوي (المقر العالمي)
• سان فرانسيسكو، كاليفورنيا
• كامبريدج، ماساتشوستس
• ووستر، ماساتشوستس
• برشلونة، اسبانيا
• شنغهاي، الصين
• سنغافورة

فرق بحثية علمية وطبية ماهرة

توظف أكثر من 50,000 متخصصًا حول العالم. تضم القوى العاملة البحثية 7800 عالم وباحث متخصص.

تكوين فريق البحث	عدد المحترفين
باحثين دكتوراه	3,200
الأطباء	1,600
أخصائيو البحوث السريرية	2,900

بنية تحتية قوية لتصنيع الأدوية

تدير 24 منشأة تصنيع على مستوى العالم. الطاقة الإنتاجية تتجاوز 2.5 مليار وحدة سنويا.

• أمريكا الشمالية: 9 مواقع تصنيع
• أوروبا: 8 مواقع تصنيع
• آسيا والمحيط الهادئ: 5 مواقع تصنيع
• أمريكا اللاتينية: موقعان للتصنيع

رأس مال مالي كبير للاستثمار

المقاييس المالية لعام 2023: إجمالي الإيرادات 56.2 مليار دولار. احتياطيات نقدية تبلغ 12.3 مليار دولار. ويمثل الاستثمار في البحث والتطوير 14.5% من إجمالي الإيرادات.

المقياس المالي	2023 القيمة
إجمالي الإيرادات	56.2 مليار دولار
الاحتياطيات النقدية	12.3 مليار دولار
الاستثمار في البحث والتطوير	6.4 مليار دولار
البحث والتطوير كنسبة مئوية من الإيرادات	14.5%

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: عروض القيمة

علاجات مبتكرة للحالات الطبية المعقدة

حقق عقار Humira من شركة AbbVie مبيعات عالمية بقيمة 21.4 مليار دولار في عام 2022، لمعالجة العديد من أمراض المناعة الذاتية. حققت شركة Skyrizi 5.4 مليار دولار في عام 2022، لعلاج الصدفية والتهاب المفاصل الصدفي.

العلاج	إشارة	مبيعات 2022
حميرا	التهاب المفاصل الروماتويدي	21.4 مليار دولار
سكيريزي	الصدفية	5.4 مليار دولار

منتجات صيدلانية متخصصة عالية الجودة

استثمرت شركة AbbVie 6.1 مليار دولار في البحث والتطوير في عام 2022، مع التركيز على الحلول الصيدلانية المتخصصة.

• محفظة الأورام بقيمة 5.8 مليار دولار في عام 2022
• خط إنتاج علم المناعة يدر 25.4 مليار دولار سنويًا
• تمثل علاجات علم الأعصاب شريحة سوقية بقيمة 3.2 مليار دولار

العلاجات المتقدمة في علم المناعة والأورام

منطقة العلاج	حجم السوق	معدل النمو
علم المناعة	25.4 مليار دولار	7.2%
الأورام	5.8 مليار دولار	9.5%

حلول طبية شخصية للمرضى

يستهدف نهج الطب الدقيق الذي تتبعه شركة AbbVie مجموعات محددة من المرضى من خلال علاجات مخصصة.

• حققت شركة Venclexta 2.1 مليار دولار أمريكي في علاجات السرطان المستهدفة
• تنتج شركة إمبروفيكا علاجات شخصية للأورام بقيمة 5.3 مليار دولار

تدخلات التكنولوجيا الحيوية المتطورة

إن إنفاق البحث والتطوير البالغ 6.1 مليار دولار في عام 2022 يدعم أبحاث التكنولوجيا الحيوية المتقدمة.

منطقة التكنولوجيا الحيوية	الاستثمار	محفظة براءات الاختراع
ابتكارات علم المناعة	2.7 مليار دولار	387 براءة اختراع نشطة
التكنولوجيا الحيوية للأورام	1.9 مليار دولار	264 براءة اختراع نشطة

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: العلاقات مع العملاء

المشاركة المباشرة مع المتخصصين في الرعاية الصحية

تحافظ AbbVie على مشاركتها المباشرة من خلال:

قناة المشاركة	التفاعلات السنوية
مندوبي المبيعات	8,500 ممثل ميداني
اتصالات العلوم الطبية	1,200 متخصص متخصص
منصات الطبيب الرقمية	أكثر من 75000 متخصص في الرعاية الصحية متصلون

برامج دعم المرضى

تقدم AbbVie خدمات دعم شاملة للمرضى:

• برنامج مساعدة المرضى يغطي أكثر من 40 مجالًا علاجيًا
• الدعم المالي يصل إلى 4.2 مليار دولار سنويا
• برامج المساعدة في الدفع المشترك لـ 15 فئة رئيسية من الأدوية

منصات الصحة الرقمية وموارد المرضى

منصة رقمية	مقاييس المستخدم
مساعد MyAbbVie	1.3 مليون مريض مسجل
بوابة تثقيف المرضى عبر الإنترنت	2.7 مليون زائر فريد سنويًا
تطبيقات الصحة المتنقلة	5 تطبيقات متخصصة لإدارة الأمراض

خدمات الاستشارة الطبية الشخصية

تشمل عروض الاستشارة المتخصصة ما يلي:

• خط ساخن مخصص لدعم التمريض للتعامل مع 350.000 استفسار سنوي
• استشارات الرعاية الصحية عن بعد بلغ متوسطها 42000 تفاعل شهري
• خدمات إدارة الأدوية الشخصية

مبادرات التعليم الطبي المستمر

برنامج التعليم	الوصول السنوي
ورش العمل الطبية المهنية	تدريب 12,500 متخصص في الرعاية الصحية
منصات التعلم عبر الإنترنت	68.000 من المهنيين الطبيين المسجلين
الندوات البحثية	رعاية 35 مؤتمرا دوليا

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: القنوات

قوة المبيعات المباشرة لمقدمي الرعاية الصحية

تمتلك AbbVie قوة مبيعات عالمية تضم 6500 ممثل يستهدفون متخصصي الرعاية الصحية في مجالات علاجية متعددة. في عام 2023، أعلنت الشركة عن تفاعلات مبيعات مباشرة مع ما يقرب من 85000 من مقدمي الرعاية الصحية في الولايات المتحدة.

متري قوة المبيعات	بيانات 2023
إجمالي مندوبي المبيعات	6,500
تفاعلات مقدمي الرعاية الصحية	85,000
متوسط مدة مكالمة المبيعات	12-15 دقيقة

شبكات توزيع الأدوية

تستخدم شركة آبفي 3 قنوات توزيع الأدوية الأولية:

• أميريسورس بيرغن
• شركة ماكيسون
• صحة الكاردينال

الموزع	حصة السوق	حجم التوزيع السنوي
أميريسورس بيرغن	35%	1.2 تريليون دولار
شركة ماكيسون	30%	1.05 تريليون دولار
صحة الكاردينال	25%	900 مليار دولار

منصات المعلومات الطبية عبر الإنترنت

استثمرت شركة AbbVie 78 مليون دولار أمريكي في منصات المعلومات الطبية الرقمية في عام 2023، حيث وصلت إلى ما يقرب من 250 ألف متخصص في الرعاية الصحية من خلال القنوات الرقمية.

المؤتمرات والندوات الطبية

وفي عام 2023، شاركت AbbVie في 127 مؤتمرًا طبيًا دوليًا، بمشاركة إجمالية بلغت 45000 متخصص في الرعاية الصحية.

نوع المؤتمر	عدد المؤتمرات	إجمالي المشاركين
المؤتمرات الطبية الدولية	127	45,000
الندوات العلاجية المتخصصة	62	22,500

قنوات التسويق والاتصال الرقمي

تتضمن استراتيجية التسويق الرقمي لشركة AbbVie ما يلي:

• شبكة LinkedIn المهنية: 150.000 اتصال مهني
• التواصل الطبي على تويتر: 85 ألف متابع
• التسويق المستهدف عبر البريد الإلكتروني: 275000 جهة اتصال متخصصة في الرعاية الصحية

القناة الرقمية	حجم الجمهور	معدل المشاركة
ينكدين	150,000	4.2%
تويتر	85,000	3.7%
التسويق عبر البريد الإلكتروني	275,000	5.1%

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: شرائح العملاء

مقدمي الرعاية الصحية والمستشفيات

تخدم AbbVie أكثر من 16,000 منشأة للرعاية الصحية على مستوى العالم. تشمل مقاييس العملاء الرئيسية ما يلي:

شريحة	عدد العملاء	المشاركة السنوية
المستشفيات	4,250	3.2 مليار دولار في المشتريات
العيادات التخصصية	6,800	1.8 مليار دولار في المشتريات
المراكز الطبية الأكاديمية	520	750 مليون دولار في المشتريات

المرضى الذين يعانون من حالات طبية مزمنة ومعقدة

تقسيم شريحة المريض:

• مرضى التهاب المفاصل الروماتويدي: 350 ألفاً
• مرضى الصدفية: 275.000
• مرضى كرون: 180.000
• مرضى التهاب الكبد الوبائي سي: 95.000

الممارسين الطبيين المتخصصين

التخصص	عدد الممارسين	حجم الوصفات الطبية السنوية
أطباء الروماتيزم	8,500	1.2 مليون وصفة طبية
أطباء الجلد	6,200	850.000 وصفة طبية
أطباء الجهاز الهضمي	4,700	620.000 وصفة طبية

مؤسسات البحوث الصيدلانية

مقاييس التعاون البحثي:

• الشراكات البحثية النشطة: 42
• الاستثمار البحثي السنوي: 2.1 مليار دولار
• المؤسسات البحثية التعاونية: 87

أنظمة الرعاية الصحية العالمية

المنطقة	أنظمة الرعاية الصحية المخدومة	اختراق السوق السنوي
الولايات المتحدة	2300 نظام	15.4 مليار دولار
أوروبا	1,750 نظام	8.7 مليار دولار
آسيا والمحيط الهادئ	1100 نظام	5.3 مليار دولار

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: هيكل التكلفة

نفقات واسعة النطاق للبحث والتطوير

وفي عام 2022، استثمرت شركة AbbVie 7.4 مليار دولار أمريكي في نفقات البحث والتطوير، وهو ما يمثل حوالي 16.8% من إجمالي الإيرادات. ومن المتوقع أن يصل إنفاق الشركة على البحث والتطوير لعام 2023 إلى 7.6 مليار دولار.

سنة	نفقات البحث والتطوير	نسبة الإيرادات
2022	7.4 مليار دولار	16.8%
2023	7.6 مليار دولار	16.9%

استثمارات التجارب السريرية

تخصص شركة AbbVie موارد كبيرة للتجارب السريرية في مجالات علاجية متعددة. ويتراوح الإنفاق السنوي المقدر للتجارب السريرية بين 1.2 مليار دولار و1.5 مليار دولار.

• التجارب السريرية للأورام: حوالي 450 مليون دولار
• التجارب السريرية لعلم المناعة: حوالي 350 مليون دولار
• التجارب السريرية لعلم الأعصاب: حوالي 250 مليون دولار

تكاليف التصنيع والإنتاج

وبلغ إجمالي نفقات التصنيع لشركة AbbVie في عام 2022 حوالي 12.3 مليار دولار، وهو ما يمثل 28% من إجمالي الإيرادات.

فئة تكلفة التصنيع	حساب
تكاليف التصنيع المباشرة	8.7 مليار دولار
تكاليف التصنيع غير المباشرة	3.6 مليار دولار

نفقات التسويق والمبيعات

وفي عام 2022، وصلت نفقات التسويق والمبيعات لشركة AbbVie إلى 13.9 مليار دولار، وهو ما يمثل حوالي 31.6% من إجمالي الإيرادات.

• الحملات التسويقية العالمية: 5.2 مليار دولار
• تعويضات قوة المبيعات: 4.7 مليار دولار
• مبادرات التسويق الرقمي: 1.6 مليار دولار
• برامج مشاركة العملاء: 2.4 مليار دولار

الامتثال التنظيمي والنفقات القانونية

وقدرت النفقات التنظيمية والقانونية السنوية لشركة AbbVie بمبلغ 850 مليون دولار في عام 2022.

فئة الامتثال	حساب
تكاليف الإيداع التنظيمية	350 مليون دولار
عمليات الإدارة القانونية	300 مليون دولار
مصاريف التقاضي والتسوية	200 مليون دولار

شركة AbbVie Inc. (ABBV) - نموذج الأعمال: تدفقات الإيرادات

مبيعات الأدوية الطبية

إجمالي إيرادات AbbVie لعام 2023: 59.2 مليار دولار

أعلى الأدوية الموصوفة	الإيرادات السنوية
حميرا	21.4 مليار دولار
سكيريزي	5.8 مليار دولار
رينفوق	4.7 مليار دولار

الترخيص ودخل حقوق الملكية

إيرادات التراخيص لعام 2023: 1.2 مليار دولار

• شراكات الترخيص الرئيسية مع شركات الأدوية
• اتفاقيات ترخيص براءات الاختراع
• اتفاقيات نقل التكنولوجيا

خطوط الإنتاج الصيدلانية المتخصصة

منتج متخصص	إيرادات 2023
منتجات الأورام	3.9 مليار دولار
منتجات الأعصاب	2.6 مليار دولار
منتجات المناعة	6.5 مليار دولار

إيرادات التوزيع في السوق العالمية

توزيع الإيرادات الجغرافية 2023:

المنطقة	الإيرادات
الولايات المتحدة	42.3 مليار دولار
أوروبا	8.7 مليار دولار
الأسواق الدولية	8.2 مليار دولار

أرباح محفظة العلاج العلاجي

المنطقة العلاجية	إيرادات 2023
علم المناعة	26.1 مليار دولار
الأورام	5.4 مليار دولار
علم الأعصاب	3.2 مليار دولار

AbbVie Inc. (ABBV) - Canvas Business Model: Value Propositions

The core value proposition for AbbVie Inc. is a strategic pivot: moving from reliance on a single blockbuster drug to a diversified, high-growth portfolio of next-generation, differentiated therapies. This isn't just a product shift; it's a financial reset designed to deliver premium, predictable growth for shareholders while offering patients superior clinical outcomes in complex disease areas.

Here's the quick math: the combined 2025 sales forecast for the two key immunology assets, Skyrizi and Rinvoq, is on pace to exceed $25 billion, which is more than enough to offset the decline of Humira, whose 2025 US sales are expected to be around $3.5 billion. This transition is the value proposition in action.

Treating severe chronic diseases (Immunology, Oncology, Neuroscience)

AbbVie's primary value is solving the toughest, high-cost problems in specialty medicine, focusing on areas where unmet patient need is still significant. This concentration allows for high-margin pricing and deep expertise.

The company focuses its efforts on three major therapeutic areas, which are expected to drive the vast majority of its 2025 revenue of approximately $60.9 billion.

• Immunology: Treating debilitating conditions like psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD) with targeted, next-generation biologics and small molecules.
• Neuroscience: Addressing complex neurological and psychiatric disorders, including Parkinson's disease, migraine, and major depressive disorder, with products like Vraylar and Botox Therapeutic.
• Oncology: Developing novel treatments for challenging blood cancers and solid tumors, leveraging assets like Imbruvica and Venclexta.

The Neuroscience portfolio alone is expected to generate global sales of approximately $10.5 billion for the full year 2025.

Offering best-in-class or first-in-class therapeutic options

The value here is clinical superiority-offering treatments that are simply better than what came before. This is how AbbVie secures favorable formulary access and physician preference, even at a premium price.

The company's strategy is built on launching drugs with differentiated mechanisms of action (MOA) that demonstrate superior efficacy or better dosing convenience. Skyrizi (risankizumab), an Interleukin-23 (IL-23) inhibitor, and Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, are the clearest examples of this value proposition.

• Skyrizi: Achieved global market leadership in psoriasis, with 2025 sales projected to hit approximately $17.3 billion.
• Rinvoq: Rapidly expanding across IBD and new rheumatology indications, with strong performance across all approved indications.

This focus on clinical differentiation is what allows them to command a premium in the market.

Improving patient quality of life with targeted therapies

For the end-user-the patient-the value is a significantly better quality of life. For a patient with severe psoriasis, a treatment that clears their skin completely is transformative. This is the human side of the financial model.

AbbVie's newer therapies offer a value proposition that extends beyond just disease control:

• Deep Efficacy: Achieving high levels of disease clearance (e.g., complete skin clearance in psoriasis) that older therapies often couldn't reach.
• Convenience: Skyrizi, for instance, offers less frequent dosing compared to some older biologics, improving patient adherence.
• Broad Indications: Expanding the use of drugs like Rinvoq into multiple inflammatory conditions, giving physicians a single, trusted option for varied patient needs.

The consistent double-digit growth in sales for these assets defintely reflects their clinical adoption and patient satisfaction.

Delivering predictable, high-margin revenue growth for investors

The value proposition to the financial market is stability and growth, especially as the company navigates the Humira patent cliff (loss of exclusivity). The goal is to replace lost revenue with higher-growth, longer-patent-life assets.

The successful transition has led to multiple upward revisions of 2025 financial guidance throughout the year, a strong signal of predictability.

Here is a snapshot of the high-growth, high-margin portfolio driving investor value in 2025:

Portfolio/Product	2025 Full-Year Global Sales Forecast (Approx.)	Value Proposition Driver
Total Company Revenue	$60.9 billion	Overall financial stability and scale
Skyrizi (Immunology)	$17.3 billion	Best-in-class efficacy, multi-indication growth
Rinvoq (Immunology)	Combined with Skyrizi: Over $25 billion	Broad-spectrum JAK inhibitor, rapid market share gains
Neuroscience Portfolio	$10.5 billion	Fastest-growing therapeutic area, diversification
Venclexta (Oncology)	$2.8 billion	First-in-class BCL-2 inhibitor for blood cancers

The latest adjusted earnings per share (EPS) guidance was raised to a range of $10.61 to $10.65 for 2025, demonstrating the high-margin nature of these specialty drugs.

Providing therapeutic alternatives to biosimilars

This is a defensive value proposition aimed squarely at payers and healthcare systems. As Humira biosimilars enter the US market, AbbVie offers clinically superior, patent-protected alternatives that justify their premium price.

The strategy is to move patients to the next-generation therapies before they can be transitioned to a biosimilar (a copycat version of a biologic drug). This is a critical value for maintaining revenue.

• Mitigating Erosion: Humira's global sales fell to $993 million in Q3 2025, a decrease of over 55% year-over-year, but the growth of Skyrizi and Rinvoq more than compensates for this loss.
• Contracting Leverage: AbbVie can use the clinical superiority of Skyrizi and Rinvoq to negotiate favorable formulary placement, offering a differentiated product instead of competing on price with the influx of biosimilars.

The company's investment in a new US manufacturing facility, part of a $10 billion decade-long investment strategy, also signals a commitment to supply chain stability, which is a key value proposition to payers and providers.

AbbVie Inc. (ABBV) - Canvas Business Model: Customer Relationships

AbbVie's customer relationship model is fundamentally a high-touch, multi-layered approach designed to manage the complexity of specialty pharmaceuticals, focusing on three key groups: the prescribing physician, the patient, and the payer. This strategy is essential for sustaining sales momentum, especially for immunology blockbusters like Skyrizi and Rinvoq, which are projected to generate combined sales of over $25 billion for the 2025 fiscal year.

High-touch, specialized sales force for physicians and specialists

The core of AbbVie's physician relationship is a highly specialized sales force that operates on a high-touch model. This is necessary because the company's leading products, particularly in immunology, neuroscience, and oncology, are complex specialty drugs requiring deep clinical knowledge to educate prescribers on efficacy, safety, and appropriate patient selection. The success of this model is visible in the rapid uptake of key products.

For example, the neuroscience portfolio, which includes Vraylar and Botox Therapeutic, saw global net revenues rise to more than $2.8 billion in the third quarter of 2025 alone, up 20.2% year-over-year, demonstrating the success of targeted physician engagement in this complex area.

Patient support and adherence programs (e.g., co-pay assistance)

AbbVie invests heavily in patient support programs to mitigate the high out-of-pocket costs associated with specialty drugs, which is a significant barrier to adherence (taking the medicine as prescribed). The main vehicle for this is the myAbbVie Assist program, which provides free medicine to qualifying, uninsured, or underinsured patients.

This commitment is a crucial retention strategy, as about 50% of patients who discontinue therapy are not enrolled in co-pay programs. In 2024, the myAbbVie Assist program helped more than 235,000 people access their prescribed medications, a clear indicator of the scale and importance of this relationship channel.

Key components of their patient support include:

• Financial assistance: Co-pay cards and free medicine programs for eligible patients.
• Adherence support: Educational materials, nurse support lines, and injection training.
• Simplified access: Dedicated support staff to help patients navigate complex insurance paperwork.

Direct engagement with payers (insurers, PBMs) for formulary access

A significant portion of AbbVie's customer relationship effort is directed at Pharmacy Benefit Managers (PBMs) and health insurers to secure favorable formulary placement (coverage) for their high-cost drugs. This is a constant negotiation, especially for the immunology portfolio as biosimilar competition for Humira intensifies.

AbbVie has responded to the biosimilar challenge by launching its own authorized biosimilar, Cordavis, an unbranded version of Humira, which is a strategic maneuver to maintain market share and influence formulary decisions in the highly competitive 2025 PBM landscape. This engagement is critical, as unfavorable formulary status can immediately cut off patient access and sales volume.

Customer Relationship Focus Area	2025 Strategic Goal	Key Metric / Financial Impact
Physician/Specialist (Sales Force)	Drive adoption of Skyrizi and Rinvoq across all approved indications.	Skyrizi 2025 Sales: Expected $17.3 billion (raised guidance).
Patient (Support Programs)	Maximize adherence and retention for specialty drug users.	Patients Assisted (2024): Over 235,000 people via myAbbVie Assist.
Payer (Market Access)	Secure preferred or exclusive formulary access for new blockbusters.	Immunology Q3 2025 Net Revenue: $7.8 billion, up 11.9% reported.

Long-term, trust-based relationships with key opinion leaders (KOLs)

AbbVie cultivates deep, long-term relationships with Key Opinion Leaders (KOLs)-leading physicians and researchers-who influence treatment guidelines and peer prescribing behavior. This relationship is not transactional; it's built on scientific collaboration, funding for investigator-initiated studies, and speaker engagements. The goal is to ensure that the latest clinical data on products like Rinvoq and Skyrizi is disseminated accurately and persuasively within the medical community. This is defintely a soft-power relationship, but it drives hard numbers.

Digital health tools for patient education and monitoring

The company is increasingly integrating digital health technology (DHT) to enhance patient relationships and gather real-world evidence (RWE). This moves the relationship beyond the clinic visit by providing continuous, objective data on treatment outcomes.

Examples of digital engagement include:

• Wearable sensors: Used in clinical trials and potentially for post-market monitoring to track objective metrics like scratch frequency in atopic dermatitis patients.
• Digital biomarkers: Developing objective and sensitive digital biomarkers to improve the precision of clinical assessments and identify treatment responders faster.
• Integrated data: Using artificial intelligence (AI) and machine learning (ML) to integrate vast amounts of patient and molecular data to accelerate drug discovery and improve clinical trials.

This digital strategy helps to democratize health technologies, empowering patients to manage their disease more effectively and providing AbbVie with invaluable, real-time insights into product performance in the real world.

AbbVie Inc. (ABBV) - Canvas Business Model: Channels

You need to know exactly how AbbVie Inc. gets its high-value, complex medicines from the factory to the patient's hand. It's not one simple path; it's a carefully orchestrated, multi-channel system that balances high-touch specialist engagement with massive consumer awareness campaigns. The channels are the engine translating their R&D into the projected $60.9 billion in net revenues for the full year 2025.

The core of their strategy is managing a dual channel model: a highly controlled, specialty-focused network for biologics and a traditional wholesale path for non-specialty products. You can't just pick up Skyrizi at your local drugstore; the complexity demands a tighter channel.

Specialty Pharmacies and Distributors for High-Cost Biologics

For high-cost, complex treatments like the immunology blockbusters Skyrizi and Rinvoq, AbbVie relies on a tight, managed network. This ensures proper handling, patient training, and crucial reimbursement support, which is defintely a key factor in adherence.

The company uses a Specialty Pharmacy Service Network (SPSN), which, even for an open distribution drug like Rinvoq, provides product-specific support. This network includes major players, but for some oncology or rare disease drugs, the network is limited or even exclusive.

Here's the quick math: drugs like Skyrizi, which generated $4.708 billion in net revenues in the third quarter of 2025 alone, flow through this specialized channel.

AbbVie's Limited Distribution Network (LDN) products as of mid-2025 include:

• Duopa (carbidopa and levodopa)
• Elahere (telisotuzumab vedotin-tllv)
• Emrelis (telisotuzumab vedotin-tllv) - Exclusive specialty pharmacy provider is Biologics by McKesson.
• Imbruvica (ibrutinib)
• Venclexta (venetoclax)
• Vyalev (foscarbidopa and foslevodopa)

Direct Sales Force Targeting Hospitals and Specialist Clinics

The high-touch, direct-to-physician channel remains critical. You have to convince the specialist-the dermatologist, rheumatologist, or neurologist-to prescribe your drug over a competitor's. This is where AbbVie's large, specialized sales force comes in, acting as an information and relationship channel.

This channel's cost is embedded in the company's overall Selling, General, and Administrative (SG&A) expense, which stood at an adjusted 21.6 percent of net revenues in the third quarter of 2025. That's a massive investment dedicated to physician engagement, medical education, and market access support.

The sales force is focused on driving 'share capture' for key growth drivers. For example, the strategy for Skyrizi and Rinvoq is to elevate the standard of care in areas like inflammatory bowel disease (IBD), a goal executed by their field teams who target:

• Specialist clinics (e.g., rheumatology, dermatology)
• Key academic and regional hospitals
• Integrated Delivery Networks (IDNs)

Wholesalers and Retail Pharmacies for Non-Specialty Drugs

While the focus is on specialty, the traditional wholesale channel handles the bulk of their non-biologic, non-specialty portfolio. This is the classic three-tier distribution model: Manufacturer $\rightarrow$ Wholesaler $\rightarrow$ Retail Pharmacy/Dispensing Physician. Products like the pancreatic enzyme Creon or the IBS treatment Linzess/Constella, while still important, rely on this broad, efficient channel for widespread availability.

The wholesalers-AmerisourceBergen, Cardinal Health, and McKesson-serve as the primary logistics backbone, moving inventory to tens of thousands of retail locations, hospital pharmacies, and physician offices across the US and globally.

Digital Platforms and Direct-to-Consumer (DTC) Advertising

AbbVie is one of the biggest spenders in pharmaceutical Direct-to-Consumer (DTC) advertising, a channel designed to drive patient demand and dialogue with their doctor. This creates a pull effect that complements the sales force's push strategy.

Their estimated total 2025 DTC Ad Spend is $1.8 billion, making them a top spender in the industry.

This spending is heavily concentrated on their immunology and neuroscience powerhouses. For instance, in the second quarter of 2025, the TV ad spending for their top two drugs alone was substantial:

Product	Q2 2025 TV Ad Spend (Approx.)	Primary Target
Skyrizi	$100 million	Psoriasis, IBD patients
Rinvoq	$84.4 million	Inflammatory conditions patients
Vraylar	Significant spend	Bipolar disorder, depression patients

Beyond TV, the digital channel includes social media outreach and online targeted advertising, which uses tracking technologies to reach specific patient demographics. This digital spend is a key action to maintain market share against biosimilar competition for legacy drugs and to accelerate adoption for new launches.

Global Regulatory and Commercial Infrastructure

The final, overarching channel is the global infrastructure required to sell medicine in over 175 countries. This is an indirect channel, but it's the non-negotiable legal and logistical framework that enables all other channels to function.

The company must navigate separate regulatory approvals, pricing negotiations, and distribution logistics for each major market. This is evident in the revenue split for products like Humira, which, even with biosimilar competition, still generated $993 million globally in Q3 2025, a significant portion of which is international. The international footprint requires a massive commercial team, regional warehouses, and a network of in-country distributors and partners to manage the flow of goods and information.

AbbVie Inc. (ABBV) - Canvas Business Model: Customer Segments

AbbVie's customer segments are clearly defined by the high-value, complex therapies they need, which is why the company is on track for a total 2025 revenue forecast of around $60.9 billion. You need to look beyond just the patient to see the full picture; the real customers are a mix of patients, their prescribing doctors, and the payers who foot the bill.

The core of the business has shifted dramatically in 2025, moving from the legacy dominance of Humira to the rapid growth of the new immunology and neuroscience portfolios. This shift means the most valuable customers are those needing the newer, high-growth products like Skyrizi and Rinvoq.

Patients with chronic, severe conditions (e.g., psoriasis, Crohn's, RA)

This is the largest and most critical segment, representing individuals with chronic, debilitating autoimmune and inflammatory diseases. They are the ultimate consumers of AbbVie's blockbuster immunology drugs. Their need is for long-term, effective disease control, and their purchasing decision is heavily influenced by physician recommendation and payer coverage.

The financial importance of this segment is clear in the 2025 sales forecasts. Skyrizi (risankizumab) and Rinvoq (upadacitinib) are expected to generate combined sales of over $25 billion in 2025, essentially replacing the revenue lost from Humira. For example, Skyrizi alone is projected to reach $17.3 billion in sales this year, driven by its use in conditions like psoriasis and inflammatory bowel disease (IBD).

• Psoriasis and Psoriatic Arthritis: Primary users of Skyrizi and Rinvoq.
• Rheumatoid Arthritis (RA): A key indication for Rinvoq and the declining Humira.
• Inflammatory Bowel Disease (IBD): Rapidly expanding market for Skyrizi and Rinvoq, capturing around 50% of the market share in IBD indications like Crohn's disease and ulcerative colitis.

Oncologists and hematologists treating cancers (e.g., CLL, AML)

This segment consists of specialized physicians who treat blood and solid tumor cancers. They are customers because they are the gatekeepers for prescribing AbbVie's oncology portfolio, where efficacy and survival data are the primary decision drivers. The oncology segment is smaller but strategic, generating Q3 2025 net revenues of $1.682 billion.

While the legacy drug Imbruvica (ibrutinib) faces competitive pressure, with Q3 2025 sales at $706 million and declining, the growth comes from newer therapies. Venclexta (venetoclax) for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) remains a strong contributor, with Q3 2025 sales of $726 million. Plus, the recent additions like Elahere (mirvetuximab soravtansine) for ovarian cancer are diversifying the portfolio.

Neurologists and psychiatrists (e.g., migraine, depression)

These specialists are crucial prescribers for AbbVie's growing neuroscience franchise, which delivered Q3 2025 net revenues of $2.841 billion. This segment includes patients with neurological and psychiatric disorders, where AbbVie offers both therapeutic proteins and small molecules.

For neurologists, the focus is on migraine prevention and treatment, with Qulipta (atogepant) and Ubrelvy (ubrogepant) showing strong uptake. Qulipta sales surged by 64.1% in Q3 2025 to $288 million, and Botox Therapeutic is a significant revenue driver for chronic migraine and other therapeutic uses, with Q3 2025 sales of $985 million. Psychiatrists primarily prescribe Vraylar (cariprazine) for bipolar disorder and schizophrenia, which brought in $934 million in Q3 2025 sales. That's a defintely strong performance.

Global government health systems and private insurers (Payers)

This is the segment that controls market access and pricing, making them a high-stakes customer. They include large US private insurers, pharmacy benefit managers (PBMs), and government programs like Medicare and Medicaid globally. Their primary need is cost-effectiveness and budget predictability, often leading to formulary negotiations (the list of covered drugs).

The impact of this segment is quantifiable: the company's 2025 guidance already factors in a 4% net sales headwind from the Medicare Part D redesign, which is a direct cost of doing business with this customer. The shift from Humira to biosimilars is also a result of payer pressure, forcing AbbVie to offer pricing concessions to maintain any market access for the legacy product. Their decisions dictate which drugs patients can actually afford.

Physicians and specialists who prescribe their complex drugs

This segment overlaps with the therapeutic specialists above, but they are a distinct customer because AbbVie markets directly to them with clinical data, educational resources, and sales support. They are the decision-makers on which specific drug a patient receives. Their loyalty is driven by clinical data, ease of use, and patient outcomes.

The table below summarizes the prescribing specialists and their key products, showing where AbbVie focuses its commercial efforts based on 2025 product performance.

Customer/Specialist	Key Therapeutic Area	Primary AbbVie Products (2025 Focus)	Q3 2025 Revenue (in millions)
Rheumatologists, Dermatologists, Gastroenterologists	Immunology (RA, Psoriasis, IBD)	Skyrizi, Rinvoq, Humira	$7,885
Oncologists, Hematologists	Oncology (CLL, AML, Ovarian Cancer)	Venclexta, Imbruvica, Elahere	$1,682
Neurologists, Psychiatrists	Neuroscience (Migraine, Depression, Schizophrenia)	Botox Therapeutic, Vraylar, Qulipta	$2,841

You can see that the immunology specialists are currently the most important prescribers, driving the largest revenue segment. This means AbbVie's sales force and clinical education efforts are heavily weighted toward those doctors to ensure continued market share gains for Skyrizi and Rinvoq.

AbbVie Inc. (ABBV) - Canvas Business Model: Cost Structure

You're looking at AbbVie Inc.'s cost structure, and the immediate takeaway is this: it's a high-fixed-cost model driven by relentless investment in the future pipeline and aggressive market defense. The company's cost base is dominated by three major, non-negotiable investments: R&D, commercial promotion, and the complex manufacturing of biologics.

This isn't a business that scales on the cheap. You'll see massive, non-routine expenses-like multi-billion-dollar milestone payments-that dwarf the day-to-day operational costs. It's a cost-intensive strategy to replace Humira's revenue and secure future growth, and it requires a huge upfront capital commitment.

Extremely high R&D expenses, estimated at $7.5 billion in 2025

The core of AbbVie's cost structure is the massive, ongoing investment in Research and Development (R&D). This is the engine that replaces revenue lost to biosimilar competition, so it's defintely not a line item to cut. For the trailing twelve months (TTM) ending September 30, 2025, AbbVie's R&D expenditure stood at a staggering $13.291 billion.

Here's the quick math: that TTM figure is nearly double the $\$7.5$ billion estimate you might see in older models, reflecting the company's accelerated push to develop new drugs like Skyrizi and Rinvoq and expand its oncology and neuroscience pipelines. This expense is largely fixed and non-discretionary; it funds thousands of scientists, clinical trials across multiple phases, and the infrastructure to support them globally. You simply cannot be a Big Pharma player without this kind of spend.

Significant Sales, General, and Administrative (SG&A) costs for marketing

Once a drug clears R&D, the next major cost is getting it to the patient. This is where Sales, General, and Administrative (SG&A) costs come in, funding the global sales force, direct-to-consumer advertising, and administrative overhead. For the TTM ending September 30, 2025, AbbVie reported SG&A expenses of approximately $13.970 billion.

This is a high-touch, high-cost model. SG&A is essential for maintaining market share, especially for key growth drivers in Immunology and Neuroscience. For example, in the second quarter of 2025 alone, the adjusted SG&A expense represented approximately 21.0 percent of net revenues, showing just how much of the top line is immediately reinvested into commercialization. This spend is necessary to educate prescribers and drive patient adoption in competitive therapeutic areas.

Cost of Goods Sold (COGS) for complex biologic manufacturing

Manufacturing complex biologic drugs, which are large-molecule compounds derived from living systems, is inherently expensive. This drives the Cost of Goods Sold (COGS). Unlike simple chemical compounds, biologics require specialized, highly regulated facilities, stringent quality control, and a complex supply chain.

For the TTM ending September 30, 2025, AbbVie's COGS was approximately $18.048 billion. This figure reflects the high cost of producing blockbuster therapeutics like Skyrizi and Rinvoq. To be fair, while the dollar amount is large, the company maintains a strong gross margin, meaning the selling price more than covers this high production cost. The adjusted gross margin in the second quarter of 2025 was a healthy 84.4 percent.

Acquisition costs and milestone payments for pipeline expansion

These are the non-routine, strategic costs that hit the income statement hard but are critical for long-term survival. AbbVie uses acquisitions and licensing deals to quickly replenish its pipeline, and these transactions involve upfront payments, or acquired In-Process Research and Development (IPR&D), and future milestone payments.

These expenses are unpredictable, still they are a constant feature of the business model. Look at 2025:

• Q2 2025 acquired IPR&D and milestones expense was $823 million pre-tax.
• Q3 2025 acquired IPR&D and milestones expense was a massive $2.7 billion pre-tax.

These payments, totaling over $3.5 billion in just two quarters, represent strategic bets on future drugs, like the acquisition of new assets to bolster the neuroscience pipeline. They are essentially an accelerated form of R&D, buying a ready-made asset instead of building it from scratch.

Legal and IP defense costs

While the direct, routine legal budget isn't public, the cost of defending and acquiring Intellectual Property (IP) is a major, ongoing expense. AbbVie's entire business hinges on patent protection, and the cost of maintaining that moat is significant, both in litigation and political influence.

The company's lobbying efforts alone, which focus intensely on drug pricing and patent protection, cost $2.525 million in Q1 2025. But the real cost is tied to the strategic IPR&D payments, which are essentially a form of IP defense by acquiring new, protected assets. A quick summary of the major cost components for the TTM ending September 30, 2025, shows where your money is going:

Cost Component (TTM ending Sep 30, 2025)	Amount (in Billions USD)	Primary Function
Cost of Goods Sold (COGS)	$18.048	Manufacturing complex biologic drugs
Sales, General, and Administrative (SG&A)	$13.970	Marketing, sales force, and administrative overhead
Research and Development (R&D)	$13.291	Internal drug discovery and clinical trials
Acquired IPR&D and Milestones (Q2+Q3 2025)	$3.523	Strategic pipeline acquisition and IP renewal

Finance: draft a 13-week cash view by Friday that explicitly models the impact of a potential Q4 IPR&D expense in the range of the recent $2.7 billion Q3 payment.

AbbVie Inc. (ABBV) - Canvas Business Model: Revenue Streams

You're looking at AbbVie Inc.'s revenue streams right now, and the direct takeaway is clear: the company has successfully navigated the Humira biosimilar challenge by accelerating its next-generation products, particularly in Immunology and Neuroscience. The primary revenue model is product sales, but strategic licensing deals are a critical, albeit volatile, secondary stream. For the 2025 fiscal year, the company is projecting total net revenues of approximately $\mathbf{\$60.5}$ billion, a significant increase from earlier estimates.

Sales of key Immunology products (Skyrizi, Rinvoq) driving growth

The core of AbbVie's revenue is shifting decisively to its new immunology blockbusters, Skyrizi (risankizumab) and Rinvoq (upadacitinib). These products are subscription-like assets, generating recurring revenue from chronic disease patients in areas like psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD). This is a high-margin revenue stream, but it requires constant investment in clinical trials to secure new indications and maintain market access.

Combined global sales of Skyrizi and Rinvoq are projected to exceed $\mathbf{\$25}$ billion for the full year 2025, demonstrating their role as the new revenue engine. Skyrizi alone is expected to generate global revenues of approximately $\mathbf{\$17.1}$ billion in 2025, with Rinvoq contributing the remainder of the combined total.

• Skyrizi: Projected 2025 sales of $\mathbf{\$17.1}$ billion.
• Rinvoq: Strong uptake across multiple new indications.
• The ex-Humira platform grew over 22% in Q4 2024, showing the growth momentum.

Oncology portfolio revenue (Venclexta, Imbruvica)

The Oncology portfolio provides a critical, diversified revenue base, though some assets face competitive pressures. Sales here come from direct product purchases by hospitals and specialty pharmacies for cancer treatment. Imbruvica (ibrutinib), a key blood cancer drug, is expected to generate global revenues of approximately $\mathbf{\$2.9}$ billion in 2025. Venclexta (venetoclax), for leukemia, is forecast to bring in global sales of around $\mathbf{\$2.8}$ billion. The portfolio also includes newer assets like Elahere (mirvetuximab soravtansine), which is adding to the stream, reporting $\mathbf{\$170}$ million in Q3 2025.

Aesthetics and Neuroscience revenue (Botox, Vraylar)

This segment represents a significant push for diversification, blending high-growth, consumer-driven products (Aesthetics) with specialty pharmaceuticals (Neuroscience). Neuroscience global sales are projected to reach approximately $\mathbf{\$10.5}$ billion for 2025, reflecting double-digit growth.

The Aesthetics portfolio, which includes Botox Cosmetic and the Juvederm line of dermal fillers, generates revenue through direct product sales to clinics and practitioners, but it has faced some market headwinds. Q3 2025 global net revenues for Aesthetics were $\mathbf{\$1.193}$ billion. The Neuroscience segment relies on products like Vraylar (cariprazine) for bipolar disorder and schizophrenia, which generated $\mathbf{\$934}$ million in Q3 2025, and Botox Therapeutic, which added $\mathbf{\$985}$ million in Q3 2025.

Revenue Stream	Key Products	2025 Full-Year Revenue Guidance (Approx.)	Q3 2025 Global Net Revenue (Actual)
Immunology	Skyrizi, Rinvoq, Humira (declining)	Over $\mathbf{\$25.0}$ billion (Skyrizi/Rinvoq combined)	$\mathbf{\$7.885}$ billion
Neuroscience	Vraylar, Botox Therapeutic, Ubrelvy, Qulipta	$\mathbf{\$10.5}$ billion	$\mathbf{\$2.841}$ billion
Oncology	Imbruvica, Venclexta, Elahere	$\mathbf{\$5.7}$ billion (Imbruvica/Venclexta combined)	$\mathbf{\$1.682}$ billion
Aesthetics	Botox Cosmetic, Juvederm	Implied in Total Net Revenue of $\mathbf{\$60.5}$ billion	$\mathbf{\$1.193}$ billion

Estimated total revenue for the 2025 fiscal year is approximately $\mathbf{\$60.5}$ billion

The financial picture is one of successful portfolio transition. The company has raised its full-year 2025 net revenue guidance to approximately $\mathbf{\$60.5}$ billion, a strong signal of confidence in the growth of the ex-Humira portfolio. The old blockbuster, Humira, is still a revenue stream, but its global sales declined by 55.4% to $\mathbf{\$993}$ million in Q3 2025 due to biosimilar competition. That's why the new products are so defintely important.

Licensing and collaboration revenue from partnerships

Licensing and collaboration revenue is a smaller, but strategically vital, revenue stream that often comes from upfront payments or milestone payments (like acquired in-process research and development, or IPR&D, which can also be an expense). For instance, a recent deal with Glenmark Pharmaceuticals for the investigational asset ISB 2001, a potential cancer and autoimmune treatment, involved a total deal value of $\mathbf{\$1.925}$ billion. While the upfront payments are a revenue source for the partner, they represent a pipeline investment for AbbVie. The company is actively executing business development transactions, with over 30 deals since early 2024, including the acquisition of ImmunoGen and Cerevel Therapeutics, which will ultimately drive future product sales.

This strategy ensures a continuous flow of new assets, which is the lifeblood of a pharmaceutical company's long-term revenue model.

Finance: Review the $\mathbf{\$7.5}$ billion R&D allocation against pipeline milestones by the end of the quarter.